Zila Saw Palmetto Inventory Loss Offset By Strong Ester-C Sales
This article was originally published in The Tan Sheet
Executive Summary
A roughly $300,000 decrease in the value of Zila's saw palmetto inventory negatively impacted the firm's fourth quarter earnings in fiscal 2002
You may also be interested in...
Zila Nutraceuticals Ad Spend Increase Aims To Enhance Ester-C Brand
Zila Nutraceuticals will increase advertising spending 30% in fiscal 2004 to broaden awareness of its Ester-C branded vitamin C ingredient among consumers and retailers
Sales & Earnings In Brief
CNS: Fiscal 2004 revenue expected to increase 10%-13% to $85 mil.-$90 mil., President & CEO Marti Morfitt tells analysts during March 20 conference call. Morfitt projects sales growth should come from four areas noting CNS' domestic Breathe Right nasal strip, FiberChoice businesses will increase 2%-4%, while international sales should rise 10%-18%. CNS anticipates Breathe Right Snore Relief Throat Spray, which launched in mid-2002, will grow another $1 mil.-$3 mil. in sales over FY 2003, and the firm's new Breathe Right Vapor Shot! vaporizer is expected to add $4 mil.-$7 mil. in new product revenue (1"The Tan Sheet" March 17, 2003, p. 19). CNS plans to increase domestic Breathe Right ad expenditure by 10% to $22 mil., to be "split between our snoring message and our nasal congestion message," Morfitt says...
Zila Ester-C Ad Campaign Features Radio, TV Spots Debuting This Fall
Zila, Inc. division Inter-Cal Nutraceuticals will launch a nine-month national advertising campaign this fall for its Ester-C supplement ingredient